Pressure BioSciences, Inc. – Research Report
July 13, 2016
RESEARCH REPORT
Patented Technology
Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market, including in the discovery of biomarkers with a worldwide market estimated to be $26 Billion. PBI’s products are based on the unique properties of both constant (static) and alternating (pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions
Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market, including in the discovery of biomarkers with a worldwide market estimated to be $26 Billion. PBI’s products are based on the unique properties of both constant (static) and alternating (pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions
 |
 |
 |
 |
 |
 |
Annual Revenue Increase of 31% – Over 250 Systems Installed
We believe that the company is well positioned in a rapidly growing market with strong technological and economical advantages over the competition. While PBI is still in its early stages of commercialization, the company’s 2015 revenue has increased by 31% to $1.8 Million from $1.4 Million in 2014 and Q1 2016 revenue has again improved by 16% YoY from Q1 2015. PBI has already over 250 PCT systems installed worldwide and has entered into a co-marketing agreement with SCIEX, the clear market leader in the mass spec field for proteomics with a commanding market share. Based on this agreement with SCIEX and the expectations expressed by the company, we anticipate double-digit growth in 2016 and rapid growth in the years to follow
We believe that the company is well positioned in a rapidly growing market with strong technological and economical advantages over the competition. While PBI is still in its early stages of commercialization, the company’s 2015 revenue has increased by 31% to $1.8 Million from $1.4 Million in 2014 and Q1 2016 revenue has again improved by 16% YoY from Q1 2015. PBI has already over 250 PCT systems installed worldwide and has entered into a co-marketing agreement with SCIEX, the clear market leader in the mass spec field for proteomics with a commanding market share. Based on this agreement with SCIEX and the expectations expressed by the company, we anticipate double-digit growth in 2016 and rapid growth in the years to follow
Research Report
Search
RECENT PRESS RELEASES
Related Post
